DNLIDenali Therapeutics Inc.

$3B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$133M

Net Income

-$119M

EPS (Diluted)

$-0.86

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$99M

Free Cash Flow

-$101M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$123M

Stockholders' Equity

$1.0B

Cash & Equivalents

$127M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$10M	-100.0%
Gross Profit	$0	$10M	-100.0%
Operating Income	-$133M	-$105M	-25.8%
Net Income	-$119M	-$99M	-21.1%

DNLI Q4 2023 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena